Vir Biotechnology, Inc.
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026
Company newsroom
Vir Biotechnology, Inc.
NASDAQ:VIR
1 releases